Drugs.com - New Drug Approvals

FDA Approves Enflonsia (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants

RAHWAY, N.J.--(BUSINESS WIRE) June 9, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved Enflonsia (clesrovimab-cfor) for the prevention of...

Jun 9, 2025 - 23:00
 0
FDA Approves Enflonsia (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants
RAHWAY, N.J.--(BUSINESS WIRE) June 9, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved Enflonsia (clesrovimab-cfor) for the prevention of...
Read More

Tags:

Previous Article

300-plus NIH staffers demand director reverse funding and workforce cuts

Next Article

Health secretary RFK Jr. abruptly fires CDC vaccine advisory panel

Related Posts

Celltrion's Yuflyma (adalimumab-aaty) Receives FDA Interchangeability Designation for All Approved Dosage Forms and Strengths

Celltrion's Yuflyma (adalimumab-aaty) Receives FDA Inte...

May 27, 2025  0

FDA Approves Mezofy (aripiprazole) Oral Film for the Treatment of Schizophrenia

FDA Approves Mezofy (aripiprazole) Oral Film for the Tr...

May 12, 2025  0

FDA Approves Vykat XR (diazoxide choline) to Treat Hype...

May 12, 2025  0